^
    3years
    A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, Xuanzhu Biopharmaceutical Co., Ltd.
    Clinical • New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK rearrangement • ROS1 positive • ROS1 rearrangement
    |
    dexitinib (XZP-3621)